SXTC
NASDAQ · Pharmaceuticals
China Sxt Pharmaceuticals In
$2.48
+0.09 (+3.77%)
Financial Highlights (FY 2026)
Revenue
7.01B
Net Income
-13,304,443,863
Gross Margin
21.1%
Profit Margin
-189.8%
Rev Growth
-12.5%
D/E Ratio
0.05
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 21.1% | 21.1% | 67.2% | 67.2% |
| Operating Margin | -154.0% | -138.6% | 22.1% | 21.0% |
| Profit Margin | -189.8% | -180.3% | 15.9% | 16.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 7.01B | 8.01B | 998.7K | 833.6K |
| Gross Profit | 1.48B | 1.69B | 670.8K | 559.9K |
| Operating Income | -10,794,813,002 | -11,104,505,316 | 220.6K | 175.0K |
| Net Income | -13,304,443,863 | -13,686,134,960 | 158.4K | 135.2K |
| Gross Margin | 21.1% | 21.1% | 67.2% | 67.2% |
| Operating Margin | -154.0% | -138.6% | 22.1% | 21.0% |
| Profit Margin | -189.8% | -180.3% | 15.9% | 16.2% |
| Rev Growth | -12.5% | -12.5% | +6.7% | -0.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 2.12M | 2.12M | 1.27M | 1.32M |
| Total Equity | 40.50M | 40.50M | 1.77M | 1.97M |
| D/E Ratio | 0.05 | 0.05 | 0.71 | 0.67 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -10,492,533,287 | -11,393,195,362 | 317.7K | 242.4K |
| Free Cash Flow | — | — | 143.5K | 109.6K |